Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel

Explore the latest updates and expert interviews

The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Latest Videos Sessions Anemias Autoimmune Disorders Bleeding Disorders Other Disorders Conferences Features Podcasts Expert Editorial Board

Welcome to The Non-Malignant Channel.

Alongside a world-leading Editorial Board, explore the latest updates in non-malignant blood disorders. Speaking directly with the experts at international congresses, The Non-Malignant Channel brings you video interviews, podcasts, roundtable discussions and more.

Conferences

EHA 2025
IPIG 2025
EBMT 2025
ESH Erythro 2025
ASH 2024
ASCAT 2024
3:50
Using luspatercept in patients with β-thalassemia who convert to transfusion dependence late in life
Maria Dimopoulou • 20 Oct 2025
1:26
Opportunities to combine mitapivat with other therapies in clinical trials
Maria Domenica Cappellini • 15 Jun 2025
2:41
Exploring mitapivat in thalassemia & SCD: the potential upcoming approval of the agent
Maria Domenica Cappellini • 15 Jun 2025
6:38
Results of the SATISFY trial investigating mitapivat in erythrocyte membranopathies and CDA II
Thomas Doeven • 12 Jun 2025
View All Videos
2:24
A Phase IV trial assessing the switch from high-dose eculizumab to weight-based ravulizumab in PNH
Austin Kulasekararaj • 15 May 2025
1:52
The impacts of PNH and symptoms that clinicians should be aware of
Richard Kelly • 15 May 2025
0:35
Aims of the new IPIG registry: advancing the understanding of PNH biology and treatment
Jeff Szer • 15 May 2025
0:54
The current treatment landscape of PNH in Germany and across Europe
Jens Panse • 15 May 2025
View All Videos
5:44
The risk of developing leukemia after lentiviral gene therapy
Akshay Sharma • 9 Apr 2025
1:49
Investigating post-transplant infusion of rivo-cel in patients with inborn errors of immunity
Mattia Algeri • 31 Mar 2025
1:58
The role of palliative care in patients with sickle cell disease undergoing SCT or gene therapy
Akshay Sharma • 9 Apr 2025
3:21
The selection of patients with transfusion-dependent thalassemia for alloSCT or gene therapy
Mattia Algeri • 31 Mar 2025
View All Videos
1:28
The growing role of gene editing and gene therapy in SCD & important practical considerations
Sara El Hoss • 21 Mar 2025
1:28
Repurposing drugs in sickle cell disease: lessons learned from hydroxyurea
Sara El Hoss • 21 Mar 2025
2:21
The impact of ineffective erythropoiesis in hemoglobinopathies & underlying mechanisms
Sara El Hoss • 21 Mar 2025
2:03
Potential therapeutic avenues being explored to target inflammation in thalassemia & SCD
Francesca Vinchi • 21 Mar 2025
View All Videos
2:23
Investigating novel variants in individuals with rare coagulation disorders
Amy Shapiro • 7 Dec 2024
1:22
The use of RNA interference-based therapies like fitusiran in hemophilia treatment
Tadashi Matsushita • 7 Dec 2024
3:28
Partners Physician Academy: the effectiveness of a program to address gaps in hemostasis training
Amy Shapiro • 7 Dec 2024
4:23
The current approaches to prophylaxis in hemophilia and tailoring treatment to the individual
Amy Shapiro • 7 Dec 2024
View All Videos
2:47
Sickle cell retinopathy: prevalence and managing patients with this complication
Christiana Dinah • 2 Oct 2024
2:07
Important considerations when managing a pediatric patient with sickle cell disease
David Rees • 3 Oct 2024
3:01
The feasibility of hydroxyurea mobile directly observed therapy in patients with SCD in SSA
Enrico Novelli • 30 Sep 2024
2:21
Hydroxyurea and follicular density in females with SCD, and the importance of fertility preservation
Jean-Hugues Dalle • 3 Oct 2024
View All Videos

The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Gold Supporter

Agios

If you are interested in becoming a supporter of The Non-Malignant Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals